• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'

    7/24/24 9:25:29 AM ET
    $AXSM
    $SAP
    $TRMD
    $TT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $AXSM alert in real time by email

    On CNBC's “Mad Money Lightning Round,” Jim Cramer said TORM plc (NASDAQ:TRMD) has a “remarkably high dividend yield. And as long as it has that dividend yield, the stock's going to stay up. But, when things start going bad, and they always do in this business, that yield's going to start going down.”

    On July 23, Evercore ISI Group analyst Jonathan Chappell maintained TORM with an Outperform rating, while increasing the price target from $45 to $48.

    Cramer recommended buying Trane Technologies plc (NYSE:TT). “Hard to stop a Trane,” he added.

    Trane Technologies will report its second-quarter financial results on Wednesday, July 31. Analysts expect the company to report quarterly earnings at $3.08 per share, up from $2.68 per share in the year-ago period. Trane is projected to post quarterly revenue of $5.13 billion compared to $4.7 billion a year ago, according to data from Benzinga Pro.

    See Also: Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock ‘Hand Over Fist’

    When asked about Axsome Therapeutics, Inc. (NASDAQ:AXSM), he said, “This is central nervous system, CNS. If you can make a breakthrough in CNS, your stock will double. If not, it will just go down. That's a double or nothing stock right there.”

    On July 22, Needham analyst Ami Fadia initiated coverage on Axsome Therapeutics with a Buy rating and announced a price target of $130.

    The “Mad Money” host said SAP SE (NYSE:SAP) is “incredible” and recommended buying the stock. “I think that SAP is not done going higher,” he added.

    On July 22, SAP reported second-quarter earnings of 82 cents per share which missed the analyst consensus estimate of $1.19 per share. Quarterly sales came in at $8.92 billion which missed the analyst consensus estimate of $8.96 billion, representing an 8.81% increase over sales from the same period last year, according to data from Benzinga Pro.

    Price Action:

    • Torm shares gained 2% to settle at $40.45 on Tuesday.
    • Trane shares rose 2.3% to settle at $344.96.
    • Sap rose 7.1% to close at $214.76 during Tuesday's session.
    • Axsome Therapeutics shares fell 0.5% to settle at $85.66 on Tuesday.

    Read Next:

    • Best Buy, Kroger And 2 Other Stocks Insiders Are Selling
    Get the next $AXSM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXSM
    $SAP
    $TRMD
    $TT

    CompanyDatePrice TargetRatingAnalyst
    SAP SE
    $SAP
    6/17/2025Overweight
    Piper Sandler
    Axsome Therapeutics Inc.
    $AXSM
    6/3/2025$185.00Outperform
    Oppenheimer
    SAP SE
    $SAP
    5/23/2025$320.00 → $330.00Outperform
    BMO Capital Markets
    SAP SE
    $SAP
    5/20/2025Overweight
    Wells Fargo
    Trane Technologies plc
    $TT
    5/1/2025$475.00Equal-Weight → Overweight
    Stephens
    Trane Technologies plc
    $TT
    4/25/2025$415.00Hold → Buy
    HSBC Securities
    SAP SE
    $SAP
    4/23/2025$300.00 → $320.00Outperform
    BMO Capital Markets
    SAP SE
    $SAP
    4/16/2025$307.00 → $300.00Outperform
    BMO Capital Markets
    More analyst ratings

    $AXSM
    $SAP
    $TRMD
    $TT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)

      NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that data from across the SYMBRAVO® (meloxicam and rizatriptan) clinical program will be presented at the 67th Annual Scientific Meeting of the American Headache Society (AHS), being held June 19-22, 2025, in Minneapolis, Minnesota. Details for the presentations are as follows: Title: Efficacy of SYMBRAVO® (MoSEIC™ meloxicam and rizatriptan) by Baseline Migraine-Associated Disability: Post-Hoc Analysis of the INTERCEPT TrialLead Author: Stewart Tepper, MD, Clinical Pro

      6/18/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders

      NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, is proud to recognize Migraine and Headache Awareness Month alongside the Association of Migraine Disorders. In honor of this year's theme, "Your Path to Better Days," Axsome is supporting more than a dozen Miles for Migraine Run, Walk or Relax events across the U.S. throughout the month of June and beyond. Axsome is also sharing resources for patients and their loved ones affected by migraine. "As someone who lives with migraine, I know how isolating, debilitating, and misunderstood this disease can

      6/16/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

      NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, including two featured oral plenary sessions, on AXS-12 and solriamfetol, at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 8-11, 2025, in Seattle, Washington. Details for the presentations are as follows: AXS-12 Title: ENCORE: Topline Results of a Phase 3 Open-Label Extension and Randomized-Withdrawal Trial of AXS-12 in NarcolepsyLead Author: Richard Bogan, MD, FCCP, FAASM, Associate Clinical Professor

      6/11/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    $SAP
    $TRMD
    $TT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on SAP SE

      Piper Sandler initiated coverage of SAP SE with a rating of Overweight

      6/17/25 7:50:57 AM ET
      $SAP
      Computer Software: Prepackaged Software
      Technology
    • Oppenheimer initiated coverage on Axsome Therapeutics with a new price target

      Oppenheimer initiated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $185.00

      6/3/25 7:47:30 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets reiterated coverage on SAP SE with a new price target

      BMO Capital Markets reiterated coverage of SAP SE with a rating of Outperform and set a new price target of $330.00 from $320.00 previously

      5/23/25 7:49:28 AM ET
      $SAP
      Computer Software: Prepackaged Software
      Technology